Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$78.87
▼ $0.60 (-0.8%)
Market data updated: 09/19 06:04 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$1.80B
Day Range
$78.51 - $79.60
52-Week Range
$78.27 - $118.01
Beta
—
Next Earnings
04.11.2026
Support
$78.27
Resistance
$106.26
LMAT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-15.6% (1Y)
Strengths: 11/27 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 30.6%
Growth
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.34 (3y annualized return 11.1% / max drawdown 32.9%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
54
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
71
Quality
58
Value
50
Momentum
19
Risk
48
Sentiment
74
Fundamental
77
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of LeMaitre Vascular, Inc. (LMAT) has primarily focused on its stock performance and financial outlook, particularly after a **31% drawdown** following a **guidance cut** in Q2 earnings. Analysts discussed the company’s **dividend status** as a "Challenger" amid dividend changes, while comparisons with rival stocks (e.g., PAHC, GEHC) highlighted valuation debates. The company’s participation in **investor conferences** in September was noted, alongside investor questions about **Artegraft growth** and margin potential. Overall, themes include **stock volatility, earnings concerns, and investor scrutiny**.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about LeMaitre Vascular, Inc.. News trend score: 74. Reason: 7 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
12
🎯 Conviction (vs. Emotion)
41
Psychology
85
Fundamentals
77
Technical
19
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-16%
Market Narrative
51
Fundamental Reality
41
Narrative Gap
+10
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
LMAT’s psychology is dominated by **anchoring** (73), where traders fixate on the 1.4% proximity to support, possibly delaying decisive action. **Loss aversion** (60) suggests lingering reluctance to accept deeper losses, while **herding** (43) hints at passive alignment with peers’ underperformance rather than active chasing. The **narrative gap** (9) implies a slight disconnect between market perception and fundamentals, but no extreme bias like FOMO or panic is evident. The key question: *Will traders break the anchor at support, or will loss aversion sustain hesitation?*
Updated: 09/09/2026, 09:28 AM
What could change this?
👥 What the crowd believes
"Dividend activity recap for Champions, Contenders & Challengers: dividend changes plus upcoming ex-dividend and pay dates."
"LeMaitre Vascular stock remains a Buy after a 31% pullback... 31% undervalued? LeMaitre Vascular (LMAT) After Earnings Guidance And Dividend Update"
"PAHC or LMAT: Which Is the Better Value Stock Right Now?... GEHC or LMAT: Which Is the Better Value Stock Right Now?"
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Benjamin Graham — 25/100
🗣️ Why do they disagree?
The stark divide in verdicts for LMAT reflects deep methodological contrasts between growth-oriented, cyclical, and value-driven investors. At the top, Bagehot’s near-perfect score highlights the stock’s liquidity resilience, while Nelson and Smith’s high marks suggest it’s positioned well in a market cycle and suited for long-term holding—both favoring structural strength. Meanwhile, Marks (Market Cycle) and Lynch’s growth focus reinforce the idea that the stock aligns with upward momentum, though Marks’ broader approach flags potential overvaluation. Fisher and Veblen’s moderate scores imply solid but not exceptional fundamentals, while the sharp drop-off to Graham’s low scores reveals the stock’s failure to meet traditional defensive metrics, signaling higher risk or speculative traits. Livermore’s outright rejection underscores a bearish trend bias, while Housel’s low score hints at volatility that could deter patient investors—showing how even high-growth candidates can clash with behavioral or trend-following frameworks.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 94
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 86
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 81
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 80
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 75
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 75
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 73
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 67
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 62
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 58
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 50
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 40
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 35
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 10 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
71.5%
Operating Margin
27.2%
Net Margin
23.1%
EBITDA Margin
31.4%
ROE
14.7%
ROA
9.4%
ROIC
—
EPS
$2.55
Cash
$28.24M
Total Debt
—
Current Ratio
12.89
Debt/Equity
—
אין נתונים היסטוריים זמינים.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 20.8.2026 | $0.250 |
| 21.5.2026 | $0.250 |
| 20.5.2026 | $0.250 |
| 12.3.2026 | $0.250 |
| 11.3.2026 | $0.250 |
| 20.11.2025 | $0.200 |
| 19.11.2025 | $0.200 |
| 21.8.2025 | $0.200 |
| 20.8.2025 | $0.200 |
| 15.5.2025 | $0.200 |
| 14.5.2025 | $0.200 |
| 13.3.2025 | $0.200 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$17.16
Tangible Book Value per Share (Tangible NAV)
$12.84
Sentiment based on basic keywords (not AI) — 7 positive, 10 neutral, 3 negative out of the last 20 articles.
Benzinga · 8.9.2026
Yahoo · 4.9.2026
StockStory · 4.9.2026
Yahoo · 2.9.2026
Zacks · 2.9.2026
Yahoo · 1.9.2026
Insider Monkey · 1.9.2026
SeekingAlpha · 28.8.2026
Yahoo · 27.8.2026
GlobeNewswire · 27.8.2026
StockStory · 15.8.2026
SeekingAlpha · 14.8.2026
Zacks · 13.8.2026
StockStory · 13.8.2026
SeekingAlpha · 13.8.2026
Motley Fool · 12.8.2026
Simply Wall St. · 8.8.2026
GlobeNewswire · 6.8.2026
MT Newswires · 6.8.2026
Insider Monkey · 6.8.2026
LeMaitre Vascular, Inc. (LMAT) currently has a StockIQ AI score of 54/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
LMAT currently scores 54/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
LMAT's technical score is 19/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 30.6%; Net income growth: 31.1%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Calmar: 0.34 (3y annualized return 11.1% / max drawdown 32.9%); Price is below the 50-day average; Price is below the 200-day average.
Yes — LMAT has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Roush John A | Grant/Award from Employer | 3.9.2026 | 0.885 | +0.885 | — |
| Roush John A | Grant/Award from Employer | 3.9.2026 | 1.664 | +1.664 | — |
| Roush John A | Grant/Award from Employer | 3.9.2026 | 1.002 | +1.002 | — |
| Kamke Trent G | Grant/Award from Employer | 3.9.2026 | 1.96 | +1.96 | — |
| Roush John A | Grant/Award from Employer | 3.9.2026 | 0.65 | +0.65 | — |
| Kamke Trent G | Grant/Award from Employer | 3.9.2026 | 3.674 | +3.674 | — |
| Kamke Trent G | Grant/Award from Employer | 3.9.2026 | 1.635 | +1.635 | — |
| Roush John A | Grant/Award from Employer | 3.9.2026 | 0.543 | +0.543 | — |
| Kamke Trent G | Grant/Award from Employer | 3.9.2026 | 0.956 | +0.956 | — |
| LeMaitre George W | Grant/Award from Employer | 3.9.2026 | 19.587 | +19.587 | — |
| Kamke Trent G | Grant/Award from Employer | 3.9.2026 | 2.193 | +2.193 | — |
| Kamke Trent G | Grant/Award from Employer | 3.9.2026 | 2.483 | +2.483 | — |
| Kamke Trent G | Grant/Award from Employer | 3.9.2026 | 0.956 | +0.956 | — |
| LeMaitre George W | Grant/Award from Employer | 3.9.2026 | 13.239 | +13.239 | — |
| LeMaitre George W | Grant/Award from Employer | 3.9.2026 | 9.573 | +9.573 | — |
| LeMaitre George W | Grant/Award from Employer | 3.9.2026 | 7.988 | +7.988 | — |
| LeMaitre George W | Grant/Award from Employer | 3.9.2026 | 11.685 | +11.685 | — |
| LeMaitre George W | Grant/Award from Employer | 3.9.2026 | 4.673 | +4.673 | — |
| LeBlanc Dorian Paul | Grant/Award from Employer | 3.9.2026 | 3.674 | +3.674 | — |
| LeMaitre George W | Grant/Award from Employer | 3.9.2026 | 4.673 | +4.673 | — |
| LeBlanc Dorian Paul | Grant/Award from Employer | 3.9.2026 | 2.886 | +2.886 | — |
| O'Connor John James | Grant/Award from Employer | 3.9.2026 | 1.664 | +1.664 | — |
| Jasinski Lawrence J | Grant/Award from Employer | 3.9.2026 | 1.664 | +1.664 | — |
| Pellegrino Joseph P JR | Grant/Award from Employer | 3.9.2026 | 4.469 | +4.469 | — |
| Jasinski Lawrence J | Grant/Award from Employer | 3.9.2026 | 0.65 | +0.65 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,521,649 shares short as of 2026-08-31 · vs. 1,446,289 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
68.1% of trading volume this week was short selling, vs. 72.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology